From: Vitamin B6 deficiency and diseases in elderly people – a study in nursing homes
Variable | All participants n=61 | Participants with p-PLP deficiency n=30 | Participants with normal p-PLP n=31 | p-value |
---|---|---|---|---|
Females | 39 (63.9%) | 20 (66.7%) | 19 (61.3%) | 0.667 |
Age (years) | 85.3 (6.8) | 87.2 (6.1) | 83.5 (7.0) | 0.032 |
Able to give informed consent | 12 (19.7%) | 5 (16.7%) | 7 (22.6%) | 0.607 |
Reside in dementia units | 24 (39%) | 10 (33%) | 14 (45%) | 0.351 |
Body mass index (kg/m2) (n=54) | 25.7 (4.5) | 25.2 (4.7) | 26.1 (4.3) | 0.467 |
p-PLP (nmol/L) | 20.7 (<4.0-175.8) | |||
Dietary vit. B6 (mg/day) females (n=38) | 1.18 (0.31) | 1.13 (0.28) | 1.22 (0.34) | 0.353 |
Dietary vit. B6 (mg/day), males (n=22) | 1.60 (0.30) | 1.53 (0.35) | 1.66 (0.26) | 0.332 |
MNA-score (n=52) | 22.5 (11–27) | 21.5 (11–27) | 22.5 (13.5-26.5) | 0.172 |
Dietary grain products (items/day) | 11.6 (3.7) | 11.6 (4.6) | 11.6 (2.8) | 0.984 |
Dietary fibre (g/day) | 18.4 (6.6) | 18.6 (8.1) | 18.2 (4.8) | 0.791 |
Steps per day (n=54) | 200 (0–5000) | 100 (0–1500) | 500 (0–5000) | 0.016 |
Katz’ ADL-index1 (n=60) | 4 (0–6) | 4 (0–6) | 3 (0–6) | 0.127 |
ALAT below reference value (< 10 U/L) | 14 (23.0%) | 11 (36.7%) | 3 (9.7%) | 0.014 |
Albumin (g/L) | 39.1 (3.6) | 38.0 (3.9) | 40.1 (2.9) | 0.022 |
Homocysteine (μmol/L) | 18.6 (10.5) | 21.5 (11.6) | 15.8 (8.5) | 0.032 |
Glomerular filtration rate2 (mL/min) (n=56) | 56.6 (19.9) | 55.4 (22.2) | 57.7 (18.0) | 0.660 |
Number of drugs used | 6 (1–13) | 5 (1–13) | 6 (1–13) | 0.372 |
Polypharmacy (> 3 drugs) | 49 (80.3%) | 21 (70.0%) | 28 (90.3%) | 0.052 |
Use of vit. B6 supplements (ATC A11) | 14 (23.0%) | 0 (0.0%) | 14 (45.2%) | <0.001 |
Use of sedatives/ hypnotics (ATC N05C) | 14 (23.0%) | 2 (6.7%) | 12 (38.7%) | 0.003 |
Use of SSRI (ATC N06AB) | 23 (37.7%) | 7 (23.3%) | 16 (51.6%) | 0.023 |
Use of anti-dementia drugs (ATC N06D) | 16 (26.2%) | 4 (13.3%) | 12 (38.7%) | 0.025 |